<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05099094</url>
  </required_header>
  <id_info>
    <org_study_id>BD311</org_study_id>
    <nct_id>NCT05099094</nct_id>
  </id_info>
  <brief_title>VEGFA-targeting Gene Therapy to Treat Retinal and Choroidal Neovascularization Diseases</brief_title>
  <official_title>A Safety and Efficacy Study of VEGFA-targeting Gene Therapy to Treat Refractory Retinal and Choroidal Neovascularization Diseases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai BDgene Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eye &amp; ENT Hospital of Fudan University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanghai BDgene Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients who respond to anti-VEGF therapy but with refractory retinal and choroidal&#xD;
      neovascularization diseases including neovascular age-related macular degeneration (nAMD),&#xD;
      diabetic macular edema (DME), and retinal vein occlusion-Macular edema (RVO-ME).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Choroidal and retinal angiogenesis diseases are a group of diseases characterized by&#xD;
      choroidal or retinal angiogenesis. These diseases are often correlated with the macular area,&#xD;
      which may lead to significant visual loss. In this study, The IDLV vector is engineered to&#xD;
      carry the VEGFA antibody gene. The gene is delivered to the RPE cells to express the VEGFA&#xD;
      antibody which neutralizes the VEGFA activity in the posterior segment of the eye of&#xD;
      individuals who have progressed to various forms of neovascular macular degeneration.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">November 25, 2021</start_date>
  <completion_date type="Anticipated">September 2023</completion_date>
  <primary_completion_date type="Anticipated">September 2023</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment-related adverse events</measure>
    <time_frame>At multiple timepoints after infusion up to 12 months.</time_frame>
    <description>Observe and record incidences of AE and SAE related to VEGFA-targeting gene therapy drug BD311 (IDLV expressing VEGFA antibody) administration.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in macular intraretinal fluid (IRF)</measure>
    <time_frame>At multiple timepoints after infusion up to 12 months.</time_frame>
    <description>The presence of macular intraretinal fluid (IRF) will be determined by optical coherence tomography (OCT).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in subretinal fluid (SRF)</measure>
    <time_frame>At multiple timepoints after infusion up to 12 months.</time_frame>
    <description>The presence of subretinal fluid (SRF) will be determined by optical coherence tomography (OCT).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in central retinal thickness (CRT)</measure>
    <time_frame>At multiple timepoints after infusion up to 12 months.</time_frame>
    <description>Central retinal thickness will be measured by Optical Coherence Tomography (OCT).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the area of choroidal neovascularization</measure>
    <time_frame>At multiple timepoints after infusion up to 12 months.</time_frame>
    <description>Using Fluorescein angiography (FFA) and indocyanine green angiography (ICGA) to assess the areas of choroidal neovascularization. Only for patients with nAMD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the area of fluorescein leakage</measure>
    <time_frame>At multiple timepoints after infusion up to 12 months.</time_frame>
    <description>Using Fluorescein angiography (FFA) and indocyanine green angiography (ICGA) to assess the areas of fluorescein leakage. Only for patients with nAMD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of rescue treatments</measure>
    <time_frame>At multiple timepoints after infusion up to 12 months.</time_frame>
    <description>Rescue treatments that require vitreous anti-VEGF injections due to illness.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the visual improvement</measure>
    <time_frame>At multiple timepoints after infusion up to 12 months.</time_frame>
    <description>Subjects will be examined for best corrected visual acuity (BCVA).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Neovascular Age-related Macular Degeneration</condition>
  <condition>Diabetic Macular Edema</condition>
  <condition>Retinal Vein Occlusion</condition>
  <arm_group>
    <arm_group_label>BD311 Adults single group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administered by suprachoroidal injection. Dosage form: injection solution. Dose: 500uL. Frequency of administration: one time injection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>BD311</intervention_name>
    <description>Integration-deficient lentiviral vector (IDLV) expressing VEGFA antibody</description>
    <arm_group_label>BD311 Adults single group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with nAMD at the age ≥50; Or patients with diabetic macular edema (DME) at&#xD;
             the age ≥18; Or patients with macular edema following retinal vein occlusion (RVO-ME)&#xD;
             at the age ≥18.&#xD;
&#xD;
          2. Early Treatment Diabetic Retinopathy Study (ETDRS) best corrected visual acuity ≤63&#xD;
             and letter score ≥19 Corresponding Snellen vision ≤20/63 and ≥20/400).&#xD;
&#xD;
          3. OCT confirms the presence of intraretinal fluid or subretinal fluid in the fovea.&#xD;
&#xD;
          4. Have received anti-VEGF therapy in the past and have responded to anti-VEGF therapy.&#xD;
&#xD;
          5. With refractory conditions: repeated anti-VEGF treatments are required due to the&#xD;
             disease condition. When the treatment is interrupted, the disease condition recurs&#xD;
             (OCT examination indicates increased subretinal/inner effusion in the macula)&#xD;
&#xD;
          6. For patients with both eyes suffered, enroll the one with more severe condition.&#xD;
&#xD;
          7. Routine blood test, liver and kidney function, coagulation index of patients is&#xD;
             normal：AST/ALT &lt; 2.5 × ULN; TB &lt; 1.5 × ULN; PT &lt; 1.5 × ULN; Hb &gt; 10 g/dL (male) and &gt;&#xD;
             9 g/dL (female); PLT &gt; 100 × 10^3/µL; eGFR &gt; 30 mL/min/1.73 m^2.&#xD;
&#xD;
        Subjects voluntarily join the study, sign an informed consent form, have good compliance,&#xD;
        and cooperate with follow-up.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Choroidal neovascularization or macular edema induced by other diseases.&#xD;
&#xD;
          2. Any other factors that affect vision improvement in the study eye, such as fibrosis,&#xD;
             atrophy, or RPE tear in the fovea of the macula.&#xD;
&#xD;
          3. The study eye already has severe proliferative retinopathy, such as retinal&#xD;
             neovascularization, traction retinal detachment, etc. (only for DME and RVO-ME&#xD;
             patients) .&#xD;
&#xD;
          4. Retinal detachment or advanced glaucoma in the study eye.&#xD;
&#xD;
          5. Implants in the study eye (except intraocular lenses).&#xD;
&#xD;
          6. Received internal eye surgery within 3 months prior to enrollment.&#xD;
&#xD;
          7. Vitrectomy surgery on the study eye.&#xD;
&#xD;
          8. Received intravitreal glucocorticoid or other clinical research drugs (except&#xD;
             anti-VEGF therapy) within 6 months prior to enrollment.&#xD;
&#xD;
          9. Myocardial infarction, cerebrovascular accident or transient ischemic attack occurred&#xD;
             within 6 months prior to enrollment.&#xD;
&#xD;
         10. Poorly controlled hypertension under maximum medication (systolic blood pressure&gt;180&#xD;
             mmHg, diastolic blood pressure&gt;100 mmHg).&#xD;
&#xD;
         11. Poor blood glucose control under medication (fasting blood glucose is greater than or&#xD;
             equal to 10.0 umol/L).&#xD;
&#xD;
         12. Women who are willing to give birth; pregnant/breastfeeding women Have received gene&#xD;
             therapy in the past.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gezhi Xu, Dr</last_name>
    <role>Study Director</role>
    <affiliation>Eye &amp; ENT Hospital of Fudan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yujia Cai, PhD</last_name>
    <phone>17721291876</phone>
    <email>yujia.cai@bdgene.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ting Xu</last_name>
    <phone>17721291876</phone>
    <email>ting.xu@bdgene.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Eye &amp; ENT Hospital of Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gezhi Xu</last_name>
      <phone>86-21-54237900</phone>
      <email>medcenter@fudan.edu.cn</email>
    </contact>
    <contact_backup>
      <last_name>Jiaxu Hong</last_name>
      <phone>86-21-54237900</phone>
      <email>medcenter@fudan.edu.cn</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 18, 2021</study_first_submitted>
  <study_first_submitted_qc>October 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 29, 2021</study_first_posted>
  <last_update_submitted>October 28, 2021</last_update_submitted>
  <last_update_submitted_qc>October 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Retinal diseases</keyword>
  <keyword>Choroidal diseases</keyword>
  <keyword>Neovascularization</keyword>
  <keyword>nAMD</keyword>
  <keyword>neovascular age-related macular degeneration</keyword>
  <keyword>DME</keyword>
  <keyword>Diabetic macular edema</keyword>
  <keyword>RVO-ME</keyword>
  <keyword>Retinal vein occlusion-Macular edema</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Retinal Vein Occlusion</mesh_term>
    <mesh_term>Wet Macular Degeneration</mesh_term>
    <mesh_term>Choroidal Neovascularization</mesh_term>
    <mesh_term>Neovascularization, Pathologic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

